Product model SPC-VET-DH671 is supplied as spectinomycin (actinospectacin) dihydrochloride pentahydrate, an aminocyclitol antibiotic obtained by submerged fermentation of Streptomyces spectabilis. The crystalline substance has the molecular formula C₁₄H₂₄N₂O₇·2HCl·5H₂O and a molecular mass of 495.35 g/mol; the theoretical spectinomycin base content is 671 µg/mg. The product is assigned CAS number 22189-32-8 for the dihydrochloride pentahydrate salt and is intended exclusively as a veterinary-grade active pharmaceutical ingredient for tablets, injections, capsules, powders, granules, premix, and solutions. The antibacterial mechanism is inhibition of protein synthesis at the 30S ribosomal subunit, with particular activity against susceptible Escherichia coli, Salmonella spp., Pasteurella multocida, and Mycoplasma gallisepticum. Storage in tightly closed, light-resistant containers at controlled room temperature is required; exposure to relative humidity above 60% may induce surface hydration and caking that reduces blend flow on vibratory feeders.

The product is manufactured under ICH Q7 and VICH GL18 conditions. Residual solvent control follows USP 467 and ICH Q3C. Industrial HPLC method validation under ICH Q2(R1) is required for each dosage form because the molecule contains two basic amine centres and a neutral aminocyclitol ring; chromatographic retention is strongly mobile-phase pH dependent. Acidified phosphate buffers at pH 2.5 with ion-pair reagent are commonly used to resolve spectinomycin from related aminocyclitol impurities. The product is released only after identity, assay, water content, and microbial limit testing; injectable campaigns additionally require bacterial endotoxin and bioburden monitoring.

What Release Specifications Govern the Veterinary API for Aqueous and Dry Dosage Forms?

The release specification is multi-dosage-form dependent because oral powders and premix require different particle size, endotoxin, and water activity limits than injectable solutions. The following table lists representative release parameters for the dihydrochloride pentahydrate salt.

The values in Table 1 are representative release criteria for a multi-dosage-form veterinary API. Individual marketing authorization files may apply narrower internal limits; all acceptance ranges must be confirmed against the approved monograph and the receiving manufacturer’s validation protocol. In addition, polymorphic identity should be verified by X-ray powder diffraction under USP 941 because the pentahydrate, anhydrous, and amorphous forms differ in aqueous solubility and compression behaviour.

For direct compression tableting, the API is typically milled to a D90 of 120–150 µm. The material has a needle-like or plate-like habit that may increase compressibility variability; a force-displacement profile on a single-station instrumented press should be generated before scaling to rotary presses. On a rotary press equipped with a force feeder operating at 20–40 rpm and turret speeds of 20–40 min⁻¹, fill weight RSD should be held below 2.0%. Tablet hardness of 5–8 kp and disintegration time ≤ 15 min in 0.1 N hydrochloric acid are typical target ranges for immediate-release formulations, but the specific monograph must govern. For capsules, dry blending with glidant and lubricant is followed by gravity or dosator filling. The powder should have a poured bulk density of 0.35–0.55 g/mL and tapped bulk density of 0.55–0.75 g/mL; Carr index often falls between 20–35% and indicates passable flow. Powder-filled hard gelatin capsules should be stored with desiccant because the gelatin shell can transfer water to the API and alter the hydrate state. Granules for sachets and premix are prepared by roller compaction or low-moisture wet granulation; residual moisture after drying is controlled to 12–18% to maintain the pentahydrate lattice while allowing downstream size reduction.

When Spectinomycin Dihydrochloride Pentahydrate Is Selected for Injectable Solutions

The injectable grade must meet bacterial endotoxin control of ≤ 0.50 EU/mg and is processed under ISO Class 7 or better according to 21 CFR 210/211 and EU GMP Annex 1. The API is freely soluble in water; a 10% w/v solution shows pH 3.5–5.0, which supports sterilising filtration through 0.2 µm polyether sulfone or polyvinylidene fluoride membrane filters. Terminal sterilisation by autoclaving at 121°C for 15 min may be acceptable if solution pH and stability data demonstrate no degradation; otherwise aseptic filtration is preferred. Tonicity adjustment with sodium chloride is required to 250–350 mOsm/kg for parenteral administration. Aqueous solutions for injection should be filled under nitrogen if oxygen-sensitive trace impurities are a concern, and they should be used within 24 h after reconstitution unless a validated preservative system is present.

For oral solution and water medication, the API is reconstituted in potable water at ambient temperature. The solubility is high enough to prepare 10–20% w/v stock solutions, but solution pH should be monitored because alkaline dilution water may raise pH above 8.0 and accelerate hydrolysis. Buffering with citric acid-sodium citrate to pH 4.0–5.0 is common. If free chlorine residual is present, dechlorination is recommended to avoid oxidative degradation. The solution should be protected from light and consumed within 24 h; beyond this interval potency loss is formulation-specific. Fixed-combination water medication with lincomycin hydrochloride in base ratios of 2:1 or 1:1 is used to extend coverage against Mycoplasma and susceptible E. coli. The two APIs are physically compatible in dry premix; in aqueous solution the pH must be maintained in the weakly acidic range. Batch charges should be calculated by base activity, not by salt weight: 671 µg/mg for spectinomycin dihydrochloride pentahydrate and the corresponding base assay for lincomycin hydrochloride.

Comparative Formulation Behaviour Against Sulfate and Aminoglycoside APIs

The dihydrochloride pentahydrate differs from spectinomycin sulfate and from veterinary aminoglycosides in several formulation-relevant respects. The pentahydrate stoichiometry fixes the theoretical base potency at 671 µg/mg; the sulfate salt has a different counterion mass and requires a separate base-activity correction. Aqueous solubility of the dihydrochloride pentahydrate is free, whereas the anhydrous base is less readily wetted; this makes the pentahydrate preferable for concentrated injectable and oral stock solutions. The molecule is an aminocyclitol without the glycosidic amino-sugar substituents present in gentamicin, neomycin, and streptomycin; consequently its ribosomal binding produces a narrower Gram-negative and Mycoplasma spectrum and a different pH-dependent stability envelope. Unlike gentamicin sulfate, which is commonly supplied as a ready-to-use injectable solution, spectinomycin dihydrochloride pentahydrate is distributed as a dry powder for reconstitution to limit aqueous degradation during shelf life. The substance is incompatible with strong alkali, oxidising agents, and ammonia-releasing excipients; it should not be autoclaved in the presence of oxidising preservatives.

Manufacture of premix requires staged dilution. The API is first blended with a small portion of calcium carbonate or lactose monohydrate, passed through a 1.0 mm screen, and then transferred to a ribbon blender filled to 50–70% working volume. Blend uniformity is assessed by sampling at least 10 locations using HPLC; acceptance is 90–110% of label claim with RSD ≤ 5.0%. Over-blending beyond 30 min may increase electrostatic segregation and should be avoided unless a formal blend-time study demonstrates otherwise. Granules for sachet dosing are produced by dry granulation using roller compaction; granule friability is controlled to prevent powder generation during packaging. Process analytical technology may be used to track water activity during discharge.

Release under ICH Q7 and VICH GL18 requires complete documentation of the fermentation strain, solvent residues, and critical impurity profile. The API is packaged in double low-density polyethylene liners inside aluminium-laminated fibre drums. A retest interval of 24 months from manufacture is typical when storage is maintained at 25°C and 60% RH; published data for this specific configuration is limited if the powder is micronized below D90 50 µm because specific surface area and moisture uptake increase. Incoming quality control should include identity, assay, water content, and microbial limits before use in non-sterile oral manufacturing; injectable campaigns additionally require endotoxin and bioburden monitoring.

Thermal Dehydration and Moisture Migration in Multi-Component Granules

Differential scanning calorimetry of the pentahydrate shows a dehydration endotherm associated with loss of lattice water; dryers and granulators must operate below the onset temperature of dehydration determined for the specific batch. The theoretical water content is 18.18%. In multi-component granules containing hygroscopic excipients, moisture migration from excipient to API can cause local dehydration or surface dissolution and subsequent interparticle bridges. Packaging with desiccant and sealed aluminium foil is used when the formulation contains deliquescent carriers such as citric acid. The dried granule is sized through an oscillating granulator fitted with 1.0–1.5 mm screen; screen pressure is adjusted to minimise undersized fines that may segregate in the final packaging step. For capsules and sachets, open handling time at relative humidity above 60% should be limited to 2 h unless air-conditioning controls are validated.